Clinical trials
Phase 3 Pulmonary Embolism trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
72 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 9 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Recruiting | 12 |
| Terminated | 10 |
| Withdrawn | 4 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 4 |
| Bristol-Myers Squibb | 4 |
| McMaster University | 4 |
| Regeneron Pharmaceuticals | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Crux Biomedical | 3 |
| Daiichi Sankyo | 3 |
| GlaxoSmithKline | 3 |
| Sanofi | 3 |
| Academic and Community Cancer Research United | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Embolism | 72 |
| Venous Thrombosis | 42 |
| Venous Thromboembolism | 32 |
| Thrombosis | 7 |
| Hemorrhage | 5 |
| Neoplasms | 5 |
| Thromboembolism | 5 |
| Atrial Fibrillation | 2 |
| COVID-19 | 2 |
| Intracranial Thrombosis | 2 |
Trials
Showing 51 to 72 of 72. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.